Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

Summit Therapeutics announced that it had entered into an agreement with Daiichi Sankyo and AstraZeneca to jointly advance a clinical trial combining Ivonescimab and Datroway.

Full text unavailableWorking from the headline and excerpt

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

Summit Therapeutics announced that it had entered into a joint development agreement with Daiichi Sankyo and AstraZeneca for a clinical trial combining Ivonescimab and Datroway. The treatment under consideration is a combination of Datroway, a TROP2-directed antibody-drug conjugate (ADC), and Ivonescimab.

The collaboration is intended to evaluate combination therapies involving biopharmaceuticals, with clinical evaluation expected to draw on the companies’ respective data and expertise.

At a glance

PartnerDaiichi Sankyo and AstraZeneca to jointly consider clinical trials

Drug combinationAdvance a combination clinical trial of Ivonescimab and Datroway

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

2/ 2 agree

All of them report the same thing.

www.businesswire.comNews

PrimaryOpen

seekingalpha.comNews

PrimaryOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.